Bivalent human papillomavirus (HPV) vaccine effectiveness correlates with phylogenetic distance from HPV vaccine types 16 and 18.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Bogaards, Johannes Avan der Weele, Pascal
Woestenberg, Petra J
van Benthem, Birgit H B
King, Audrey J
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Bivalent human papillomavirus (HPV) vaccine effectiveness correlates with phylogenetic distance from HPV vaccine types 16 and 18.Published in
J Infect Dis 2019; 220(7):1141-6PMID
31165164ae974a485f413a2113503eed53cd6c53
10.1093/infdis/jiz280
Scopus Count
Collections
Related articles
- No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
- Authors: Woestenberg PJ, King AJ, van der Sande MA, Donken R, Leussink S, van der Klis FR, Hoebe CJ, Bogaards JA, van Benthem BH, Medical Microbiological Laboratories., Public Health Services.
- Issue date: 2017 Apr
- Choosing the optimal HPV vaccine: The health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries.
- Authors: Burger EA, Portnoy A, Campos NG, Sy S, Regan C, Kim JJ
- Issue date: 2021 Feb 15
- Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Type-Specific Effectiveness and Evidence of Cross-Protection.
- Authors: Kudo R, Yamaguchi M, Sekine M, Adachi S, Ueda Y, Miyagi E, Hara M, Hanley SJB, Enomoto T
- Issue date: 2019 Jan 9
- Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands.
- Authors: Woestenberg PJ, King AJ, Van Benthem BHB, Leussink S, Van der Sande MAB, Hoebe CJPA, Bogaards JA, Medical Microbiological Laboratories and the Public Health Services.
- Issue date: 2020 Mar 28
- Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
- Authors: Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmerón J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M, HPV PATRICIA Study Group.
- Issue date: 2012 Jan